DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Analysts Set New Price Targets
DXCM has been the subject of several analyst reports. Wells Fargo & Company reduced their price objective on DexCom from $144.00 to $102.00 in a research report on Friday, July 29th. Citigroup reduced their price objective on DexCom from $105.00 to $100.00 in a research report on Friday, July 29th. Oppenheimer reduced their price objective on DexCom from $131.00 to $105.00 in a research report on Friday, July 29th. Morgan Stanley reduced their price objective on DexCom from $91.00 to $83.00 and set an "equal weight" rating for the company in a research report on Friday, July 29th. Finally, Sanford C. Bernstein initiated coverage on DexCom in a research report on Friday, July 15th. They set an "outperform" rating and a $105.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $115.23.
DexCom Price Performance
Shares of NASDAQ:DXCM traded down $0.45 during trading on Friday, hitting $89.09. The company had a trading volume of 2,220,084 shares, compared to its average volume of 2,754,997. The company has a market cap of $34.97 billion, a P/E ratio of 185.61, a PEG ratio of 3.56 and a beta of 1.03. DexCom has a 52 week low of $66.89 and a 52 week high of $164.86. The business's 50-day moving average is $86.60 and its 200 day moving average is $98.41. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.30 and a current ratio of 4.72.
DexCom (NASDAQ:DXCM - Get Rating) last posted its quarterly earnings results on Thursday, July 28th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.02). The company had revenue of $696.20 million during the quarter, compared to the consensus estimate of $709.33 million. DexCom had a net margin of 7.47% and a return on equity of 11.79%. DexCom's quarterly revenue was up 17.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.19 EPS. Equities research analysts predict that DexCom will post 0.79 earnings per share for the current fiscal year.
Insider Buying and Selling at DexCom
In other DexCom news, Director Steven Robert Pacelli sold 1,000 shares of the company's stock in a transaction on Monday, July 25th. The stock was sold at an average price of $83.07, for a total value of $83,070.00. Following the transaction, the director now owns 138,700 shares of the company's stock, valued at $11,521,809. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other DexCom news, EVP Chad Patterson sold 777 shares of the business's stock in a transaction on Monday, May 9th. The shares were sold at an average price of $342.77, for a total transaction of $266,332.29. Following the sale, the executive vice president now directly owns 13,675 shares of the company's stock, valued at approximately $4,687,379.75. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Steven Robert Pacelli sold 1,000 shares of the business's stock in a transaction on Monday, July 25th. The shares were sold at an average price of $83.07, for a total transaction of $83,070.00. Following the sale, the director now directly owns 138,700 shares in the company, valued at $11,521,809. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,627 shares of company stock valued at $676,977. Corporate insiders own 0.41% of the company's stock.
